Immunome, Inc.
NASDAQ:IMNMBiotechnology
-$0.42 today
- Market cap
- $1.98B
- Beta
- 2.07
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$1.99
Volume 1.41M
Average 1.23M
IMNM Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Immunome, Inc.NASDAQ: IMNM
Operating Income · Q3 FY2026 · quarter ended Sep 2026
Operating income remains negative
Q3 FY2026 operating income was -$90.36M, compared with -$60.14M a year earlier. Trailing-twelve-month operating income was -$300.69M.
Context
- Operating income amounted to 3084.8% of revenue in FY2025, down 297.6 pp from a year earlier.
- Operating income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether operating income reaches the consensus estimate from 7 analysts of -$221.64M (-3.5%) for the fiscal year ending Dec 2026, a slowdown from the +30.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$90.36M-15.6% QoQ
- Last fiscal yearDec 2025
- -$214.11M+30.0% YoY
- LTMSep 2026
- -$300.69M-28.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -50.3% | -12.9% | +37.4 pp |
| 1 year | +30.0% | -3.5% | -33.5 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (214.11M) USD
- Year-over-year change
- +30.0%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (214.11M) | +30.0% |
| FY2024 | 2024-12-31 | (305.8M) | -179.2% |
| FY2023 | 2023-12-31 | (109.53M) | -196.8% |
| FY2022 | 2022-12-31 | (36.9M) | -46.4% |
| FY2021 | 2021-12-31 | (25.2M) | — |
Operating Income vs competitors
How IMNM compares with its peers on the latest reported figures
- Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -28.4% is the 6th highest of 11, against a peer median of -21.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$29.36M USD | +38.3% | — | 7.6% | |
| LTM Mar 2026 | -$36.08M USD | -65.8% | — | — | |
| LTM Sep 2026 | -$39.45M USD | -46.4% | — | — | |
| LTM Mar 2026 | -$47.93M USD | -53.5% | — | — | |
| LTM Mar 2026 | -$63.66M USD | +36.0% | — | 40.5% | |
| LTM Mar 2026 | -$115.08M USD | +54.0% | — | 115.5% | |
| LTM Mar 2026 | -$156.87M USD | -11.7% | — | — | |
| LTM Mar 2026 | -€212.71M EUR | -251.5% | — | 570.3% | |
| LTM Mar 2026 | -$242.4M USD | +2.4% | — | 381.8% | |
| LTM Sep 2026 | -$300.69M USD | -28.4% | — | — | |
| LTM Sep 2026 | -$334.5M USD | -30.5% | — | 298657.1% | |
| Peer median (excluding IMNM) | — | -21.1% | — | 248.6% | |
Competitors are the stored peer set for IMNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 14.02M | 9.04M | 6.94M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 2.96M |
| Gross Profit | 0 | 0 | 14.02M | 9.04M | 3.99M |
| Gross Margin | — | — | 100.0% | 100.0% | 57.4% |
| Research & Development | 14.11M | 23.27M | 23.09M | 129.54M | 174.33M |
| Selling, General & Admin | 11.09M | 13.63M | 19.66M | 32.96M | 43.77M |
| Operating Expenses | 25.2M | 36.9M | 123.55M | 314.84M | 218.1M |
| Depreciation & Amortization | 755K | 631K | 728K | 2.1M | 2.96M |
| EBITDA | (23.95M) | (36.26M) | (28M) | (151.35M) | (209.44M) |
| EBITDA Margin | — | — | -199.7% | -1674.1% | -3017.4% |
| Operating Income | (25.2M) | (36.9M) | (109.53M) | (305.8M) | (214.11M) |
| Operating Margin | — | — | -781.4% | -3382.4% | -3084.8% |
| Interest Income | 10K | 5K | 2.72M | 12.84M | 11.72M |
| Interest Expense | 10K | 5K | 0 | 0 | 0 |
| Other Income / Expenses | 493K | 5K | 2.72M | 12.84M | 1.72M |
| Income Before Tax | (24.71M) | (36.9M) | (106.81M) | (292.96M) | (212.39M) |
| Pre-Tax Margin | — | — | -761.9% | -3240.4% | -3060.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (24.71M) | (36.9M) | (106.81M) | (292.96M) | (212.39M) |
| Net Margin | — | — | -761.9% | -3240.4% | -3060.0% |
| EPS (Basic) | (2.14) | (3.09) | (5.38) | (5.00) | (2.43) |
| EPS (Diluted) | (2.14) | (3.09) | (5.38) | (5.00) | (2.43) |
| Weighted Avg Shares | 11.54M | 12.13M | 19.84M | 58.64M | 87.35M |
| Weighted Avg Shares (Diluted) | 11.54M | 12.13M | 19.84M | 58.64M | 87.35M |
Immunome, Inc.
NASDAQ:IMNM
Intrinsic Alpha fair value
Locked
Current Price
$16.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.